Latest News
Incyte Touts Positive 52-Week Results from a Randomised Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
18 October 2019 - - US-based biopharmaceutical company Incyte (NASDAQ: INCY) has received positive 52-week results from its randomised, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inh...
Harbour BioMed Completes Phase 2 Study in China of HBM9036 In Patients With Moderate-to-Severe Dry Eye Disease
18 October 2019 - - US-based biopharmaceutical company Harbour BioMed has completed a Phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe Dry-Eye-Disease, the com...
Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of AVID200, First-in-Class TGF-beta 1 and 3 Inhibitor
18 October 2019 - - US-based protein engineering company Forbius's Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 and 3 selective inhibitor, administered as a monotherapy has fully enroll...
Eyevensys Presents Initial Data from Phase I/II Trial of Innovative, Non-Viral Gene Therapy for Ocular Diseases at 11th Annual Ophthalmology Innovation Summit
18 October 2019 - - US-based biotechnology company Eyevensys has presented results from part 1 of its phase I/II study for non-infectious uveitis at the Ophthalmology Innovation Summit's 11th Annual OIS@AAO conference on October 10, 2019 in San ...
Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress
18 October 2019 - - US-based biopharmaceutical company Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) has presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to...